：origin of business
  ：Launch of main product brands

Year

News

Price of Stock Acquisition/Equity Share after Acquisition (described only since 2000)

1935

Established Takara Seiyaku Co. (the present AJINOMOTO HEALTHY SUPPLY, INC.).

1942

Established Nippon Specialty Oil Manufacturing Co., Inc. (the present Ajinomoto Fine-Techno Co., Inc.) through joint investment by Ajinomoto Co., Inc. and Nippon Oil Co.

1956
Started the amino acids for pharmaceuticals business with the launch of Essential Amino Acid Crystals (infusion materials)

1965
Started the animal nutrition business with the launch of feed-use Lysine

1971
Started the personal care ingredients business with the launch of Ajidew®

1972
Launched Personal Care Ingredients Amisoft®

1974

Established AJINOMOTO EUROLYSINE S.A.S.(later AJINOMOTO ANIMAL NUTRITION EUROPE S.A.S. ) in France (sold in 2021).

1984

Established Heartland Lysine, Inc. (the present Ajinomoto Animal Nutrition North America, Inc.) in the U.S.

1987
Began sales of Ajinomoto Serum Free (ASF) medium, Japan’s first serum-free culture medium

1988

Established TAISO COMMERCE INC. in Taiwan.

1989

Acquired S.A. OmniChem N.V. (the present S.A. Ajinomoto OmniChem N.V.).

1995
Started the sports nutrition business with the launch of amino VITAL® PRO

1997
Started the direct marketing business with the launch of JINO® cosmetics

Established Ajinomoto Lianhua Amino Acid Co., Ltd. （later HENAN AJINOMOTO AMINO ACID CO., LTD.) in China (closed in 2018).

1999

Established Ajinomoto Pharma Co., Ltd. (later AJINOMOTO PHARMACEUTICALS CO., LTD.）

Launched Ajinomoto Build-up Film(ABF), an interlayer insulating material for semiconductor packages

2005
Launched fundamental food product Glyna® (renewed in 2015 as a Food with Functional Claims)

Established Ajinomoto Medica Co., Ltd.（later AJINOMOTO PHARMACEUTICALS CO., LTD.）

2010

Established Ajinomoto Medica Co., Ltd.

2011
Launched a Lysine formulation for dairy cows AjiPro®-L.

Established Granules OmniChem Private Ltd. (India) through a joint venture with Granules India Limited
Established Ajinomoto Animal Nutrition Group, Inc.

2012

Established Ajinomoto Genexine Co., Ltd., a joint venture with South Korean biopharmaceuticals research and development company Genexine Co., Ltd. (production and sale of animal cell culture media)
Established PT Lautan Ajinomoto Fine Ingredients, a joint venture with PT Lautan Luas Tbk in Indonesia (production of Personal Care Ingredients)

2013

Acquired Althea Technologies Inc. , a U.S.-based Biopharmaceutical CDMO (sold in 2025).

Acquired Althea Technologies Inc.: approx.16.0￥billion/100%

2015

Established  Ajinomoto Fine-Techno USA Corporation.

2016

Established gastrointestinal specialty pharma EA Pharma Co., Ltd. by integrating the gastrointestinal disease business of Eisai Co., Ltd. into AJINOMOTO PHARMACEUTICALS CO., LTD.

Began sales of StemFit®, an iPS/ES cell culture medium for clinical research.

Acquired GeneDesign, Inc., a major Japanese contract development and manufacturing organization for nucleic acid drugs.

GeneDesign, Inc.,: Non-disclosure/100%

2017

Acquired Agro2Agri, S.L. (“A2A”) that has Agro-business subsidiaries in Spain.
Acquired Cambrooke Therapeutics, Inc., a medical foods company in U.S.

Agro2Agri, S.L.: Non-disclosure/Majority share
Cambrooke Therapeutics, Inc.,: approx. 7.2￥billion/100%

2018

Established a contract manufacturer for clinical-use cell culture media for regenerative medicine through a joint venture with Kohjin Bio Co., Ltd. (Ajinomoto Kohjin Bio Co., Ltd.)
Established Ajinomoto Shanghai Specialty Chemicals, Co.,Ltd. in Shanghai.

2019

Acquired remaining 50% equity share of Granules OmniChem Private Ltd. and made it a wholly owned subsidiary.

Granules OmniChem Private Ltd.: Non-disclosure/100%

2020

Acquired Nualtra Limited, a supplements company in Ireland.

Nualtra Limited: Non-disclosure/100%

2023

Acquired Forge Biologics LLC, a Gene therapy CDMO in U.S.

Forge Biologics Holdings, LLC: approx. 78.5￥billion/100%